Explainer

What Cannabis Strain Is Best for Anxiety? What Studies Show

No strain is proven best for anxiety. In a 2024 study of 300 adults, CBD-dominant flower was linked to less tension than THC-dominant; labels often mislead.

Mental Health Stats Research Team 7 min read

Key Takeaways

  • A 2025 systematic review of 57 studies, 17 of them randomized trials, found that varied products and generally low study quality prevent definitive conclusions about cannabis for anxiety[1].57 studies[1]
  • In a 2024 University of Colorado study of 300 adults with anxiety symptoms, CBD-dominant flower was linked to lower tension and paranoia right after use than THC-dominant flower[2].300 adults[2]
  • Over 30 days in a 2026 study, anxiety fell 34.8% among people using CBD flower and 39.5% with THC + CBD flower, versus 7.8% with THC-only flower[3].7.8% vs. 34.8%[3]
  • Only 1.4% of 89,923 U.S. flower samples tested in a 2022 analysis were CBD-dominant; 96.5% were THC-dominant[4].96.5%[4]
  • Labels are unreliable: 18 of 23 Colorado flower samples tested in 2023 contained less THC than the lowest value printed on the package[5].18 of 23[5]
  • FDA has not approved cannabis for the treatment of any disease or condition, including anxiety[6].None[6]

What Cannabis Strain Is Best for Anxiety? The Short Answer

No cannabis strain has been shown to be best for anxiety. Research for this article found no placebo-controlled trial of a named strain such as ACDC, Harlequin or Granddaddy Purple, and a 2025 systematic review of 57 studies found that varied study designs and generally low study quality prevent definitive conclusions about medicinal cannabis for anxiety[1].

What studies do compare is chemistry. In a 2024 study of 300 adults with anxiety symptoms, CBD-dominant flower was associated with less tension and paranoia right after use than THC-dominant flower[2]. That points to the ratio of THC to CBD, not the strain name, as the variable researchers can measure.

This article covers what those studies found and why strain names and labels are a weak guide. Prevalence data on cannabis use and cannabis use disorder are on the substance use disorder page, and anxiety figures are on the anxiety page.

Cannabis chemotype

A grouping of cannabis by measured chemical content rather than by strain name or plant shape. Researchers sort products by THC-to-CBD ratio into three chemotypes: THC-dominant, balanced THC:CBD, and CBD-dominant[4]. Products are then subdivided by terpene profile.

Related Terms

chemovar
strain
cultivar
THC:CBD ratio
terpenes

Source: Smith et al., PLOS ONE, 2022

What Studies Found When Cannabis Types Were Compared for Anxiety

The largest direct comparison comes from the University of Colorado Boulder. Researchers enrolled 258 adults with anxiety symptoms who used cannabis flower about 3 to 4 times a week and randomly assigned them to one of three legal-market products: THC-dominant (24% THC, under 1% CBD), balanced (12% THC, 12% CBD) or CBD-dominant (under 1% THC, 24% CBD)[2]. A comparison group of 42 adults with anxiety symptoms did not use cannabis[2].

Anxiety scores fell over the 4-week study in every group[2]. When frequency of use was taken into account, CBD-dominant use was associated with lower anxiety scores than THC-dominant use, and right after use it was linked to lower tension and paranoia ratings than both the THC-dominant and balanced products[2].

The authors also reported that THC did not increase anxiety in this group of regular users[2]. Participants used as much as they chose, so dose was not fixed.

A 2026 follow-up from the same research group tracked daily anxiety for 30 days in 345 adults who wanted to use cannabis for anxiety relief[3]. Among flower users, anxiety fell 39.5% in the THC + CBD group and 34.8% in the CBD group, compared with 7.8% in the THC group[3].

Edibles did not follow the same pattern. Edible users in the THC group saw a 19.9% reduction and the CBD group a 24.9% reduction, while the THC + CBD edible group was essentially unchanged (a 0.6% increase)[3].

Anxiety Results by Cannabis Chemotype in Recent Studies

StudyDesignTHC-dominantBalanced THC:CBDCBD-dominant
Bidwell et al., 2024258 users, 4 weeks, assigned product, no placeboHigher tension and paranoia after useMore tension and paranoia than CBD-dominantLowest tension and paranoia after use
Rosa et al., 2026 (flower)30-day daily diary, no placebo-7.8%-39.5%-34.8%
Rosa et al., 2026 (edibles)30-day daily diary, no placebo-19.9%+0.6%-24.9%
Kayser et al., 202012 adults with OCD, placebo-controlled crossoverLess anxiety relief than placeboNot testedLess anxiety relief than placebo

How anxiety changed by product chemistry in three studies of adults, 2020 to 2026. Percentages are changes in mean daily anxiety ratings from day 1 to day 30[3]; other rows summarize between-group comparisons[2][7].

1Rosa et al. labeled groups THC, THC + CBD and CBD; they are shown here under the matching chemotype.

2Participants in the Bidwell and Rosa studies chose how much to use, and neither study had a placebo group.

Sources

  • •Bidwell et al., Cannabis Cannabinoid Res, 2024
  • •Rosa et al., Int J Environ Res Public Health, 2026
  • •Kayser et al., Depression and Anxiety, 2020
Reduction in daily anxiety over 30 days among people using THC-only flower, versus 34.8% with CBD flower
7.8%

Adults who wanted cannabis for anxiety relief and used THC-dominant flower reported far smaller drops in anxiety than those using CBD or THC + CBD flower. The study had no placebo group, so the changes are associations, not proof of effect.

"THC + CBD and CBD products had greater decreases in anxiety (39.5% and 34.8%, respectively) compared to THC products (7.8%)"

Rosa L, et al. (Int J Environ Res Public Health)(2026) View Source

Is a High-CBD Strain Better for Anxiety Than a High-THC Strain?

The Colorado studies lean toward CBD-dominant and balanced flower, but they cannot show that either one treats anxiety. Neither study had a placebo condition, and the 2026 authors wrote that their findings should be read as associational rather than causal[3].

A placebo-controlled flower trial in an anxiety-related disorder found no advantage for either chemotype. Researchers at Columbia University had 12 adults with obsessive-compulsive disorder smoke THC-dominant (7.0% THC), CBD-dominant (10.4% CBD) and placebo cannabis in random order[7]. State anxiety was lower right after placebo than after either active product, and OCD symptoms did not differ between them[7].

The wider evidence base is thin. A 2025 systematic review found that of 57 studies on medicinal cannabis and anxiety, 17 were randomized controlled trials[1]. It concluded that varied formulations, dosing and generally low study quality limit firm conclusions about effectiveness[1].

NIH's National Center for Complementary and Integrative Health described the human evidence in 2019 as a small amount suggesting cannabis or cannabinoids might reduce anxiety, citing a 24-person study of CBD in social anxiety disorder[8]. That summary predates the Colorado studies.

How to read these studies: The Colorado studies let participants use as much cannabis as they chose and asked them to rate their own anxiety. People also chose whether to use flower or edibles, which the authors noted could bias results[3]. Changes over time may reflect expectation or the passage of time as well as the product.

Do Strain Names Like ACDC or Granddaddy Purple Predict Effects?

Strain names are not standardized, so two products sold under the same name can differ. A genetic study of 30 strains bought from dispensaries in three states found that only 4 had consistent genetic identity across all samples[9]. The authors warned that consumers could be getting inconsistent products, which matters most for patients relying on a strain for specific symptoms[9].

Chemistry data point the same way. A 2022 analysis of 89,923 flower samples from six U.S. states found that strain names were a better marker of chemistry than the indica, sativa and hybrid labels, but were "far from ideal"[4]. The broader labels are covered in Is Sativa or Indica Better for Anxiety?

The same analysis shows why CBD-dominant flower is hard to find. Of the 89,923 samples, 96.5% were THC-dominant, 2.2% were balanced and 1.4% were CBD-dominant[4]. Most strains marketed for calm are therefore THC-dominant products.

Are THC and CBD Percentages on Cannabis Labels Accurate?

Often not, which complicates any choice based on the label. When researchers tested 23 flower samples from 10 Colorado dispensaries, 18 contained less THC than the lowest value on the label[5]. On average, measured THC was 23.1% below the lowest labeled value, and about 70% of samples were more than 15% below it[5].

CBD products have a similar problem. Of 84 CBD extracts bought online from 31 companies, 30.95% were accurately labeled for CBD, 42.85% contained more CBD than labeled and 26.19% contained less[10]. THC was detected in 18 of the 84 products[10].

NCCIH notes that over-the-counter CBD products may contain more or less CBD than stated and may contain contaminants such as THC[8]. For a person trying to avoid THC because it worsens their anxiety, an unlabeled THC content is a practical concern.

What About Terpenes Like Limonene, Linalool and Myrcene?

Dispensary guides often rank strains by terpenes, the aromatic compounds that give cannabis its smell. Human trial data on terpenes and anxiety are limited to small studies.

The clearest is a 2024 Johns Hopkins trial in 20 healthy adults who used cannabis occasionally[11]. Inhaling 15 mg of d-limonene along with 30 mg of THC significantly reduced ratings of feeling "anxious/nervous" and "paranoid" compared with 30 mg of THC alone, while limonene by itself did not differ from placebo[11].

The authors cautioned that they used pure THC and pure limonene rather than whole-plant cannabis, so the results may not carry over to retail products[11]. This article did not identify a comparable human trial for linalool or myrcene and anxiety.

Can a Cannabis Strain Make Anxiety Worse?

Yes. CDC states that cannabis use can cause disorientation and sometimes unpleasant thoughts or feelings of anxiety and paranoia[12]. In the Columbia trial, THC-dominant cannabis raised heart rate and blood pressure compared with CBD-dominant cannabis and placebo[7].

CDC also reports that people who use cannabis are more likely to develop psychosis and long-lasting disorders such as schizophrenia, with a stronger link to schizophrenia among people who start young and use more often[12]. Those associations do not show that cannabis is the cause in every case.

No cannabis product is an approved anxiety treatment. FDA has approved one cannabis-derived drug, Epidiolex (purified CBD), and only for seizures linked to Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex[6]. FDA has not approved a marketing application for cannabis for any disease or condition[6].

The broader trial and long-term evidence is reviewed in Is Weed Good for Anxiety? Treatments with established trial support are covered in therapy for anxiety and anxiety medication.

Frequently Asked Questions

Sources & References

  1. Roberts L, Sorial E, Budgeon CA, Lee K, Preen DB, Cumming C. Medicinal cannabis in the management of anxiety disorders: a systematic review. Psychiatry Research. Published 2025. Accessed October 2026. https://doi.org/10.1016/j.psychres.2025.116552 [Link]
  2. Bidwell LC, Martin-Willett R, Skrzynski C, et al. Acute and extended anxiolytic effects of cannabidiol in cannabis flower: a quasi-experimental ad libitum use study. Cannabis and Cannabinoid Research. Published 2024. Accessed October 2026. https://doi.org/10.1089/can.2023.0187 [Link]
  3. Rosa L, Lisano JK, Skrzynski CJ, Bryan AD, Bidwell LC. Therapeutically motivated cannabis use for anxiety: daily and longitudinal reductions vary between flower and edible products. International Journal of Environmental Research and Public Health. Published 2026. Accessed October 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC12941097/ [Link]
  4. Smith CJ, Vergara D, Keegan B, Jikomes N. The phytochemical diversity of commercial Cannabis in the United States. PLOS ONE. Published 2022. Accessed October 2026. https://doi.org/10.1371/journal.pone.0267498 [Link]
  5. Schwabe AL, Johnson V, Harrelson J, McGlaughlin ME. Uncomfortably high: testing reveals inflated THC potency on retail Cannabis labels. PLOS ONE. Published 2023. Accessed October 2026. https://doi.org/10.1371/journal.pone.0282396 [Link]
  6. U.S. Food and Drug Administration. FDA regulation of cannabis and cannabis-derived products, including cannabidiol (CBD). FDA. Published 2024. Accessed October 2026. https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd [Link]
  7. Kayser RR, Haney M, Raskin M, Arout C, Simpson HB. Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: a human laboratory study. Depression and Anxiety. Published 2020. Accessed October 2026. https://doi.org/10.1002/da.23032 [Link]
  8. National Center for Complementary and Integrative Health. Cannabis (marijuana) and cannabinoids: what you need to know. NIH. Published 2019. Accessed October 2026. https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know [Link]
  9. Schwabe AL, McGlaughlin ME. Genetic tools weed out misconceptions of strain reliability in Cannabis sativa: implications for a budding industry. Journal of Cannabis Research. Published 2019. Accessed October 2026. https://doi.org/10.1186/s42238-019-0001-1 [Link]
  10. Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy of cannabidiol extracts sold online. JAMA. Published 2017. Accessed October 2026. https://jamanetwork.com/journals/jama/fullarticle/2661569 [Link]
  11. Spindle TR, Zamarripa CA, Russo E, et al. Vaporized d-limonene selectively mitigates the acute anxiogenic effects of delta-9-tetrahydrocannabinol in healthy adults who intermittently use cannabis. Drug and Alcohol Dependence. Published 2024. Accessed October 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC11031290/ [Link]
  12. Centers for Disease Control and Prevention. Cannabis and mental health. CDC. Published 2024. Accessed October 2026. https://www.cdc.gov/cannabis/health-effects/mental-health.html [Link]

Related Statistics